

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

精優藥業控股有限公司\*

*(Incorporated in Bermuda with limited liability)*

(Stock Code: 00858)

### CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGES IN COMPOSITION OF BOARD COMMITTEES

The board (the “**Board**”) of directors (the “**Directors**”) of Extrawell Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces the following changes of independent non-executive director of the Company (the “**INED**”) with effect from 20 January 2026.

#### RESIGNATION OF INED

The Board hereby announces that with effect from 20 January 2026, Mr. Fang Lin Hu (“**Mr. Fang**”), who has served as an INED since 11 June 2001, has resigned (the “**Resignation**”) as an INED, the chairman of each of the audit committee of the Company (the “**Audit Committee**”) and remuneration committee of the Company (the “**Remuneration Committee**”) and a member of the nomination committee of the Company (the “**Nomination Committee**”) due to his advanced age and to devote more time to his family affairs.

Mr. Fang has confirmed to the Company that he has no claim against the Company and has no disagreement with the Board. In addition, there are no other matters regarding his Resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to express its sincere gratitude to Mr. Fang for his valuable contributions to the Company during his tenure of office.

## APPOINTMENT OF INED

The Board further announces that with effect from 20 January 2026, Ms. Yang Xiaorong (“**Ms. Yang**”) has been appointed as an INED. The biographical details of Ms. Yang is set out below:

Ms. Yang, aged 54, obtained a Master of Business Administration degree from China Europe International Business School (“**CEIBS**”) (中歐國際工商學院) in 2014; and a bachelor’s degree in Administration & Political Science from Fudan University, School of Continuing Education in 2005. Ms. Yang also participated in the board secretary training programme organized by the Shanghai Stock Exchange and obtained a qualification certificate for board secretary in 2016. Ms. Yang has extensive experience in private equity, specializing in risk management, governance frameworks and institutional process design, and has experience within government-affiliated organizations in the People’s Republic of China, conversant with public-sector operations, regional economic development, and enterprise services.

Ms. Yang has been the partner of Shanghai Ruishi Private Equity Fund Management Co., Ltd. since January 2016, mainly in charge for fundraising, risk control, compliance, and overall enterprise management. Ms. Yang served as the general manager in East Malu Industrial Development Zone, Jiading District, Shanghai (上海嘉定區馬陸鎮馬東工業開發區) from January 2006 to December 2015 and as a director of Foreign Investment Office, Malu Town, Jiading District, Shanghai (上海嘉定區馬陸鎮外資辦) from January 2003 to December 2005. Ms. Yang has also been the secretary general of CEIBS Jiading Alumni Association since April 2012.

There is no service contract between Ms. Yang and the Company. Ms. Yang has entered into a letter of appointment with the Company as an INED with no fixed term. Pursuant to the letter of appointment and the bye-laws of the Company, Ms. Yang will hold office until the first annual general meeting of the Company after her appointment but will then be eligible for re-election at that annual general meeting and thereafter she shall be subject to retirement by rotation and re-election at the Company’s annual general meeting in accordance with the bye-laws of the Company. Ms. Yang is entitled to a director’s fee in the amount of HK\$70,000 per annum, which was approved by the Board with reference to the recommendation of the Remuneration Committee based on her background, qualifications, experience, her roles and responsibilities within the Company and the current market conditions.

As at the date of this announcement, save as disclosed above, Ms. Yang has confirmed that she (i) does not hold any directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years immediately preceding the date of this announcement; (ii) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong; (iii) does not have any relationship with any Directors, senior management or substantial shareholders or controlling shareholders (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”)) of the Company; (iv) does not hold any other position with the Company or any member of the Group; and (v) does not have other major appointments or professional qualifications save as disclosed herein.

Ms. Yang has also confirmed that (i) she meets all the independence factors as set out in Rule 3.13(1) to (8) of the Listing Rules; (ii) she did not and does not have any past or present financial or other interest in the business of the Group or did not and does not have any connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) there are no other factors that may affect her independence at the time of her appointment.

Save as disclosed above, the Board is not aware of other matter relating to the appointment of Ms. Yang that needs to be brought to the attention of the Shareholders and there is no other information that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to take this opportunity to welcome Ms. Yang for joining the Board.

## **CHANGES IN COMPOSITION OF BOARD COMMITTEES**

Following the Resignation and with effect from 20 January 2026, the composition of the following Board committees shall be changed as follows:

- (i) Audit Committee: Mr. Fang has ceased to be a chairman; Ms. Jin Song, an INED and an existing member, has been appointed as the chairman; Ms. Yang has been appointed as a new member.
- (ii) Remuneration Committee: Mr. Fang has ceased to be a chairman; Ms. Jin Song, an INED and an existing member, has been appointed as the chairman; Ms. Yang has been appointed as a new member.
- (iii) Nomination Committee: Mr. Fang has ceased to be a member and Ms. Yang has been appointed as a new member.

By order of the Board  
**Extrawell Pharmaceutical Holdings Limited**  
**Xie Yi**  
*Chairman*

Hong Kong, 20 January 2026

*As at the date of this announcement, the executive directors are Dr. Xie Yi, Dr. Guo Yi, Mr. Cheng Yong, Dr. Lou Yi and Ms. Wong Sau Kuen, and the independent non-executive directors are Ms. Jin Song, Dr. Zeng Li and Ms. Yang Xiaorong.*

*\* For identification purpose only*